David Huang
7PUBLICATIONS
2CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Jan 10, 2022
A Phase 1 Study To Evaluate Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Antistaphylococcal Lysin LSVT-1701 in Healthy Adult Subjects.Mary Beth Wire, Soo Youn Jun, In-Jin Jang
|Nov 24, 2021
Prospective Activity of PLG0206, an Engineered Antimicrobial Peptide, on Chronic Periprosthetic Joint Infection Total Knee Arthroplasty Components Ex Vivo: The Knee Explant Analysis (KnEA) Study.David Huang, Dana M Parker, Jonathan B Mandell
|Nov 22, 2021
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of a First-in-Human Engineered Cationic Peptide, PLG0206, Intravenously Administered in Healthy Subjects.David Huang, Despina Dobbins, Parviz Ghahramani
|Sep 25, 2020
Iclaprim reduces the incidence and severity of Staphylococcus aureus-induced septic arthritis in a murine model.D B Huang, S Noviello, C G Gemmell
|Sep 25, 2020
Evaluation of in vitro activity of iclaprim in combination with other antimicrobials against pulmonary pathogens: a pilot study.David B Huang, Cyntia de Piano, Sophie Magnet
|Nov 29, 2018
Iclaprim activity against wild-type and corresponding thymidine kinase-deficient Staphylococcus aureus in a mouse protection model.David B Huang, Jee Hyun Park, Timothy M Murphy
Pageof 2
